https://orcid.org/0000-0003-3909-182X
References
- Angiolillo DJ, Galli M, Collet JP, et al. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention. 2022;17(17):e1371–96.
- Galli M, Capodanno D, Andreotti F, et al. Safety and efficacy of P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opin Drug Saf. 2021;20(1):9–21.
- Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12(1):30–47.
- Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J. 2015;36(27):1762–1771. DOI:10.1093/eurheartj/ehv104
- Capodanno D, Bhatt DL, Gibson CM, et al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat Rev Cardiol. 2022;19(2):117–132. DOI:10.1038/s41569-021-00598-1
- Galli M, Ortega-Paz L, Franchi F, et al. Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention. Pharmacogenomics. 2022;23(13):723–737.
- Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12(16):1521–1537. DOI:10.1016/j.jcin.2019.03.034
- Galli M, Franchi F, Rollini F, et al. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev Clin Pharmacol. 2021;14(8):1–16. DOI:10.1080/17512433.2021.1927709
- Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–1830.
- Simon T, Bhatt DL, Bergougnan L, et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharm Therap. 2011;90(2):287–295.
- Galli M, Franchi F, Rollini F, et al. Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends Cardiovasc Med. 2021 Dec 20;S1050-1738(21):00157.
- Galli M, Franchi F. Guided selection of antiplatelet therapy in acute coronary syndrome: impact on outcomes and resource utilization. Int J Cardiol. 2021 Dec 15;345:36–38.
- Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y(12) inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021;14(7):739–750.
- Notarangelo FM, Maglietta G, Bevilacqua P, et al. Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLOPHARMCLO trial. J Am Coll Cardiol. 2018;71(17):1869–1877.
- Al-Rubaish AM, Al-Muhanna FA, Alshehri AM, et al. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients. Int J Cardiol. 2021;343:15–20.
- Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–1631.
- Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324(8):761–771.
- Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet (London, UK). 2021;397(10283):1470–1483.
- Galli M, Benenati S, Franchi F, et al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J. 2022 Mar 7;43(10):959–967.
- Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovasc Interv. 2020;13(5):606–617.
- Capodanno D, Angiolillo DJ, Lennon RJ, et al. ABCD-GENE score and clinical outcomes following percutaneous coronary intervention: insights from the TAILOR-PCI trial. J Am Heart Assoc. 2022;11(4):e024156.
- Laborante R, Borovac JA, Galli M, et al. Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: time to tackle the Yentl syndrome? Front Cardiovasc Med. 2022;9:1009475.